Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers
Phase 2 trial will assess the efficacy of AP31969 on atrial fibrillation burden and its safety profile using continuous cardiac rhythm monitoring
Copenhagen, Denmark, 6 January 2026 – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering treatments for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces enrolment of the first patients in its randomized, double-blind, placebo-controlled, dose finding Phase 2 clinical trial (NCT07267949), designed to assess the efficacy and safety of AP31969 in AF patients. The trial will enrol 200 patients across eight European countries, with anticipated completion by Q1 2027.
